ES2598277T3 - Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad - Google Patents
Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad Download PDFInfo
- Publication number
- ES2598277T3 ES2598277T3 ES12173008.9T ES12173008T ES2598277T3 ES 2598277 T3 ES2598277 T3 ES 2598277T3 ES 12173008 T ES12173008 T ES 12173008T ES 2598277 T3 ES2598277 T3 ES 2598277T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- macular degeneration
- administration
- subject
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002780 macular degeneration Diseases 0.000 title abstract description 41
- 238000011282 treatment Methods 0.000 title abstract description 22
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract description 10
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 title abstract description 9
- 229960002474 hydralazine Drugs 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 30
- 150000003839 salts Chemical class 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 description 56
- 229910052739 hydrogen Inorganic materials 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 19
- 102000000589 Interleukin-1 Human genes 0.000 description 18
- 108010002352 Interleukin-1 Proteins 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 16
- 230000002265 prevention Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 206010029113 Neovascularisation Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000013534 fluorescein angiography Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 229960005205 prednisolone Drugs 0.000 description 10
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 10
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 9
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000006193 liquid solution Substances 0.000 description 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- -1 that is Chemical compound 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000002997 ophthalmic solution Substances 0.000 description 5
- 229940054534 ophthalmic solution Drugs 0.000 description 5
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- CEVKXJCXJUVSPW-UHFFFAOYSA-N n,3-diphenyl-1,3-thiazinan-2-imine Chemical compound C=1C=CC=CC=1N1CCCSC1=NC1=CC=CC=C1 CEVKXJCXJUVSPW-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 3
- 235000008714 apigenin Nutrition 0.000 description 3
- 229940117893 apigenin Drugs 0.000 description 3
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- HPUXDMUGCAWDFW-UHFFFAOYSA-N Osthole Natural products COc1ccc2CCC(=O)Oc2c1C=CC(=O)C HPUXDMUGCAWDFW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 229960001293 methylprednisolone acetate Drugs 0.000 description 2
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229940021584 osthol Drugs 0.000 description 2
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- 229960004259 prednisolone tebutate Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- BLJRIMJGRPQVNF-SNVBAGLBSA-N (R)-timolol Chemical compound CC(C)(C)NC[C@@H](O)COC1=NSN=C1N1CCOCC1 BLJRIMJGRPQVNF-SNVBAGLBSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- OTMJHPDXEVPLQB-UHFFFAOYSA-N 1-nitropyrazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CN([N+]([O-])=O)N=1 OTMJHPDXEVPLQB-UHFFFAOYSA-N 0.000 description 1
- WDZVGELJXXEGPV-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methylideneamino]guanidine Chemical compound NC(N)=NN=CC1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QUGCHRRFRZOACN-UHFFFAOYSA-N 4-bromo-1-nitropyrazole Chemical compound [O-][N+](=O)N1C=C(Br)C=N1 QUGCHRRFRZOACN-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVIRJSYIWQJCSO-UHFFFAOYSA-N C1=C(O)C(O)=CC=C1C1=C(O)C(O)=C2C(O)=CC(=O)C=C2O1 Chemical compound C1=C(O)C(O)=CC=C1C1=C(O)C(O)=C2C(O)=CC(=O)C=C2O1 WVIRJSYIWQJCSO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical compound O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- FTVWIRXFELQLPI-UHFFFAOYSA-N naringenin Chemical compound C1=CC(O)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68099805P | 2005-05-12 | 2005-05-12 | |
| US680998P | 2005-05-12 | ||
| US77642606P | 2006-02-24 | 2006-02-24 | |
| US776426P | 2006-02-24 | ||
| US11/416,773 US8088773B2 (en) | 2005-05-12 | 2006-05-03 | Therapeutic compositions and methods |
| US416773 | 2006-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2598277T3 true ES2598277T3 (es) | 2017-01-26 |
Family
ID=37431545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12173008.9T Active ES2598277T3 (es) | 2005-05-12 | 2006-05-04 | Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8088773B2 (enExample) |
| EP (3) | EP2508183B1 (enExample) |
| JP (2) | JP5335419B2 (enExample) |
| AU (1) | AU2006247892B2 (enExample) |
| CA (1) | CA2608163C (enExample) |
| DE (1) | DE202006020318U1 (enExample) |
| ES (1) | ES2598277T3 (enExample) |
| PL (1) | PL2508182T3 (enExample) |
| WO (1) | WO2006124324A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2648223A1 (en) * | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders |
| US7736860B2 (en) * | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
| EP3150215A1 (en) * | 2009-08-24 | 2017-04-05 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating opthalmic conditions |
| SG11201408230VA (en) * | 2012-06-11 | 2015-01-29 | Macuclear Inc | Therapeutic formulation and methods of treatment |
| CN104955330A (zh) * | 2012-09-13 | 2015-09-30 | Cba制药有限公司 | 粉防己碱药物制剂及方法 |
| US9975910B2 (en) | 2013-07-23 | 2018-05-22 | Eisai R&D Management Co., Ltd. | Hetero-fused cyclic compound |
| US9370503B1 (en) * | 2015-02-26 | 2016-06-21 | Chi Chou Liao | Compounds for treating ocular diseases |
| FI3723752T3 (fi) | 2017-12-11 | 2024-11-13 | Artelo Biosciences Inc | Kannabidiolin uudet kiinteät olomuodot ja niiden käyttötarkoitukset |
| CN112367971A (zh) * | 2018-06-11 | 2021-02-12 | 加利福尼亚大学董事会 | 用以治疗眼睛疾病的脱甲基化 |
| CN110585196B (zh) * | 2018-06-13 | 2022-11-04 | 郭涛 | 一种治疗及预防眼科疾病的药物及其应用 |
| CN112007031A (zh) * | 2019-05-30 | 2020-12-01 | 杏国新药股份有限公司 | 眼用制剂 |
| EP3949958A1 (en) * | 2020-08-04 | 2022-02-09 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Compound for the treatment and prophylaxis of a lipofuscin-associated disease |
| CN114276251B (zh) * | 2021-12-07 | 2022-12-16 | 武汉大学 | 一种合成硝基(杂)芳烃的方法 |
| US20240285572A1 (en) * | 2023-02-27 | 2024-08-29 | Opticgon Llc | Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4055645A (en) * | 1976-02-13 | 1977-10-25 | Merck & Co., Inc. | Novel anti-hypertensive compositions |
| FI873429L (fi) * | 1986-08-18 | 1988-02-19 | Houston Biotechnology | Oftalmologiska kompositioner foer behandling av nervdegenerationer. |
| US4865599A (en) * | 1986-08-18 | 1989-09-12 | Houston Biotechnology, Inc. | Ophthalmic compositions for treating nerve degeneration |
| IT1201151B (it) | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
| US5500230A (en) * | 1987-01-23 | 1996-03-19 | The General Hospital Corporation | Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5194434A (en) * | 1991-12-03 | 1993-03-16 | Texas A&M University System | Use of OB-101 to treat ocular inflammation |
| US5252607A (en) | 1992-01-24 | 1993-10-12 | Texas A&M University System | Treatment of low pressure glaucoma and ischemic retinal degeneration |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5422166A (en) * | 1993-02-12 | 1995-06-06 | Wangner Systems Corporation | Abrasion resisting edge for a forming fabric |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| US5596011A (en) | 1995-04-06 | 1997-01-21 | Repine; Karen M. | Method for the treatment of macular degeneration |
| CN1216469A (zh) | 1996-04-26 | 1999-05-12 | 藤泽药品工业株式会社 | 含有二氢吡啶类化合物的眼组织末梢循环改善剂 |
| US6066675A (en) * | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| ES2317650T3 (es) | 1996-10-28 | 2009-04-16 | Senju Pharmaceutical Co., Ltd. | Farmacos para mejorar trastornos circulatorios oculares. |
| EP1058546A4 (en) | 1998-03-06 | 2004-07-28 | Univ Texas | COMPILATIONS AND METHODS FOR THE TREATMENT OF MACULA DISEASES |
| US6028099A (en) | 1998-03-13 | 2000-02-22 | John Hopkins University, School Of Medicine | Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization |
| WO2000000194A1 (en) * | 1998-06-27 | 2000-01-06 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
| CA2363503C (en) * | 1999-03-05 | 2009-03-10 | University Of Iowa Research Foundation | Diagnostics and therapeutics for drusen associated ocular disorders |
| IL137429A0 (en) | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
| EP1246605A2 (en) * | 1999-08-10 | 2002-10-09 | The Board Of Regents, The University Of Texas System | Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow |
| JP4372905B2 (ja) * | 1999-09-02 | 2009-11-25 | 興和株式会社 | 網膜神経細胞保護剤 |
| US20030007971A1 (en) * | 2000-01-31 | 2003-01-09 | Hideaki Hara | Remedies for ophthalmic diseases |
| AU2001259758A1 (en) * | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| US6692759B1 (en) * | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| US20030171375A1 (en) * | 2002-02-13 | 2003-09-11 | Brazzell Romulus Kimbro | Method for treating ocular neovascular diseases |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| AU2003287250B9 (en) * | 2002-10-30 | 2010-01-28 | Ptc Therapeutics, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| JP2004250347A (ja) * | 2003-02-18 | 2004-09-09 | Ajinomoto Co Inc | 網膜虚血に基づく疾患の治療および／又は予防剤 |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20080300292A1 (en) * | 2004-11-08 | 2008-12-04 | Nitromed, Inc | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders |
-
2006
- 2006-05-03 US US11/416,773 patent/US8088773B2/en not_active Expired - Fee Related
- 2006-05-04 EP EP12173011.3A patent/EP2508183B1/en not_active Not-in-force
- 2006-05-04 CA CA2608163A patent/CA2608163C/en not_active Expired - Fee Related
- 2006-05-04 ES ES12173008.9T patent/ES2598277T3/es active Active
- 2006-05-04 JP JP2008511191A patent/JP5335419B2/ja not_active Expired - Fee Related
- 2006-05-04 DE DE202006020318U patent/DE202006020318U1/de not_active Expired - Lifetime
- 2006-05-04 PL PL12173008T patent/PL2508182T3/pl unknown
- 2006-05-04 EP EP12173008.9A patent/EP2508182B1/en not_active Not-in-force
- 2006-05-04 WO PCT/US2006/017329 patent/WO2006124324A1/en not_active Ceased
- 2006-05-04 EP EP06759120A patent/EP1885371A4/en not_active Withdrawn
- 2006-05-04 AU AU2006247892A patent/AU2006247892B2/en not_active Ceased
-
2011
- 2011-11-23 US US13/304,116 patent/US20120071485A1/en not_active Abandoned
- 2011-11-23 US US13/304,088 patent/US20120115959A1/en not_active Abandoned
-
2012
- 2012-04-05 US US13/440,851 patent/US8318741B2/en not_active Expired - Fee Related
- 2012-07-18 JP JP2012159151A patent/JP5643263B2/ja not_active Expired - Fee Related
- 2012-11-05 US US13/669,318 patent/US20130059841A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120196868A1 (en) | 2012-08-02 |
| JP5335419B2 (ja) | 2013-11-06 |
| EP2508182A1 (en) | 2012-10-10 |
| EP2508183A1 (en) | 2012-10-10 |
| US8318741B2 (en) | 2012-11-27 |
| AU2006247892B2 (en) | 2010-04-22 |
| WO2006124324A1 (en) | 2006-11-23 |
| US20120115959A1 (en) | 2012-05-10 |
| US20060276458A1 (en) | 2006-12-07 |
| US20130059841A1 (en) | 2013-03-07 |
| US8088773B2 (en) | 2012-01-03 |
| EP1885371A4 (en) | 2010-04-07 |
| JP2008540528A (ja) | 2008-11-20 |
| JP5643263B2 (ja) | 2014-12-17 |
| HK1177419A1 (en) | 2013-08-23 |
| EP2508182B1 (en) | 2016-07-06 |
| US20120071485A1 (en) | 2012-03-22 |
| DE202006020318U1 (de) | 2008-07-31 |
| AU2006247892A1 (en) | 2006-11-23 |
| JP2012229257A (ja) | 2012-11-22 |
| EP1885371A1 (en) | 2008-02-13 |
| CA2608163C (en) | 2011-10-25 |
| PL2508182T3 (pl) | 2017-05-31 |
| CA2608163A1 (en) | 2006-11-23 |
| EP2508183B1 (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2598277T3 (es) | Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad | |
| ES2257768T3 (es) | Antagonistas de neurotropina para el tratamiento de epilepsia, enfermedad de alzheimer y el dolor. | |
| ES2372421T3 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos. | |
| US20060204486A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
| US20120010288A1 (en) | Method for protecting a retinal neuronal cell | |
| ES2673158T3 (es) | Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA | |
| KR20010071827A (ko) | 반점성망막 퇴행에서 신혈관 신생의 예방치료 | |
| JP2005533766A (ja) | アレルギー反応の治療方法 | |
| ES2546672T3 (es) | Formulación acuosa estable mejorada de (E)-4-carboxiestiril-4-clorobencilsulfona | |
| KR100342367B1 (ko) | 녹내장치료제및안압강하제 | |
| ES3006014T3 (en) | Use of nalfurafine for the treatment of demyelinating diseases | |
| US11622954B2 (en) | Estrogen receptor ligands, compositions and methods related thereto | |
| US20110021618A1 (en) | Methods of treating fibrotic disorders | |
| ES2860767T3 (es) | Mirabegrón para el tratamiento de enfermedades retinianas | |
| US20040039003A1 (en) | Treatment of hepatic cirrhosis | |
| EA022711B1 (ru) | Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии | |
| ES2989515T3 (es) | Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas | |
| CA2192576A1 (en) | Remedy for allergic diseases in the region of the nose | |
| IL93243A (en) | Preparations for the prevention of neurodegeneration | |
| JP4695326B2 (ja) | 鼻炎用医薬組成物 | |
| EP2599480A1 (en) | Compounds for the treatment of influenza | |
| JP2009235093A (ja) | 鼻炎用医薬組成物 | |
| ES2341517B1 (es) | Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas. | |
| AU748754B2 (en) | Treatment of hepatic cirrhosis | |
| WO1994003167A1 (fr) | Remede contre la cataracte |